CGTLive’s Weekly Rewind – May 13, 2022

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Caribou’s CRISPR-Edited CAR T-Cell Therapy CB-010 Elicits Complete Response in R/R B-NHL

Caribou will present the initial data at the upcoming European Hematology Association (EHA) meeting in June.

2. REGENXBIO DMD Gene Therapy Trial Delayed Due to Manufacturing Issue

The trial was set to begin patient dosing in the first half of this year.

3. Arcellx Doses First Patient in ARC-SparX CAR-T Program for Multiple Myeloma

The cell therapy is the first to come out of the company’s proprietary ARC-SparX platform.

4. Takeaways From Phase 1 Trial of RTX-240 in Solid Tumors: Alexander I. Spira, MD, PhD, FACP

Alexander I. Spira, MD, PhD, FACP, research institute director with Virginia Cancer Specialists Research Institute, discusses the examination of RTX-240 in a phase 1 trial with solid tumors, presented recently at the 2022 AACR Annual Meeting.

5. Gene Therapy for Overactive Bladder, Incontinence Shows Good Safety, Efficacy

The locally injected gene therapy product is the subject of an ongoing phase 2a clinical trial.